Vatelizumab
Vatelizumab
Vatelizumab (pronunciation: va-tel-iz-u-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a type of biopharmaceutical that is used in the field of immunology.
Etymology
The name "Vatelizumab" follows the INN naming convention for monoclonal antibodies, with the suffix "-mab" indicating that it is a monoclonal antibody. The prefix "Vatel-" does not have a specific meaning in the INN naming convention.
Usage
Vatelizumab is used in the treatment of various autoimmune diseases. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells. Vatelizumab works by binding to specific proteins in the body, which can help to reduce the immune system's attack on its own cells.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Autoimmune diseases: A condition in which your immune system mistakenly attacks your body.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Immunology: The branch of medicine and biology concerned with immunity.
External links
- Medical encyclopedia article on Vatelizumab
- Wikipedia's article - Vatelizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski